时间：2021-02-03 14:07:50来源： 德国新闻网
A Shenzhen-based drugmaker on Tuesday began trial production of a COVID-19 vaccine from multinational pharmaceutical company AstraZeneca.
Shenzhen Kangtai Biological Products Co. Ltd. announced that it has built a production workshop for the adenovirus vector vaccine developed by AstraZeneca and the University of Oxford, which won the approval for emergency use in the United Kingdom on Dec. 30.
The facility, with a floor area of 2,200 square meters, has an annual production capacity of 400 million doses.
The Shenzhen drugmaker signed a deal with AstraZeneca in August 2020 to introduce the latter's COVID-19 vaccine into China for which it is seeking clinical registration.
The company itself developed an inactivated coronavirus vaccine and is planning to launch phase 3 trials.
Geng Funeng: Upholding Tradition and Embracing Innovation to Expand Traditional Chinese Medicine Globally
2026-10-22
China advances local hybrid rice seed production overseas
2026-10-18
Embodied AI events to highlight 2026 China Robot Competition in Hangzhou
2026-10-13
China-Laos Railway handles over 80 million passenger trips since opening
2026-10-10
'Meet China' film program brings Chinese cinema, cultural exchanges to Paris
2026-10-05
Two giant pandas set off for 10-year stay at Zoo Atlanta in the U.S.
2026-09-27
Dual holidays plus Canton Fair to drive passenger boom at Guangzhou Baiyun Airport
2026-09-24
China Robot Summit sets standards and global roadmap for embodied AI
2026-09-20